Reparixin L-lysine salt is primarily used in medical research and therapeutic applications due to its role as a selective inhibitor of CXCR1 and CXCR2 chemokine receptors. It is being investigated for its potential to reduce inflammation and organ damage in conditions such as acute pancreatitis, ischemia-reperfusion injury, and complications following organ transplantation. In clinical trials, it has shown promise in mitigating the inflammatory response in patients undergoing pancreatic islet transplantation, improving graft survival and function. Additionally, it is being explored for its potential to alleviate symptoms in respiratory diseases, such as acute lung injury, by blocking neutrophil recruitment and activation. Its application extends to oncology, where it is studied for its ability to modulate the tumor microenvironment and enhance the efficacy of cancer therapies.